GMDP and psoriasis

Lancet. 1998 Dec 5;352(9143):1857. doi: 10.1016/S0140-6736(05)79923-2.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Comment

MeSH terms

  • Acetylmuramyl-Alanyl-Isoglutamine / adverse effects
  • Acetylmuramyl-Alanyl-Isoglutamine / analogs & derivatives*
  • Adjuvants, Immunologic / adverse effects*
  • Analysis of Variance
  • Chronic Disease
  • Humans
  • Psoriasis / drug therapy*
  • Treatment Failure

Substances

  • Adjuvants, Immunologic
  • Acetylmuramyl-Alanyl-Isoglutamine
  • glucosaminylmuramyl-2-alanine-D-isoglutamine